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Abstract
Introduction: Circulating cell-free DNA (cf-DNA) is a useful indicator of cell death, and it can also be used to predict
outcomes in various clinical disorders. Several innate immune mechanisms are known to be involved in eliminating DNA
and chromatin-related material as part of the inhibition of potentially harmful autoimmune responses. However, the exact
molecular mechanism underlying the clearance of circulating cf-DNA is currently unclear.
Methods: To examine the mechanisms controlling serum levels of cf-DNA, we carried out a genome-wide association
analysis (GWA) in a cohort of young adults (aged 24–39 years; n = 1841; 1018 women and 823 men) participating in the
Cardiovascular Risk in Young Finns Study. Genotyping was performed with a custom-built Illumina Human 670 k BeadChip.
The Quant-iTTM high sensitivity DNA assay was used to measure cf-DNA directly from serum.
Results: The results revealed that 110 single nucleotide polymorphisms (SNPs) were associated with serum cf-DNA with
genome-wide significance (p,561028). All of these significant SNPs were localised to chromosome 2q37, near the UDP-
glucuronosyltransferase 1 (UGT1) family locus, and the most significant SNPs localised within the UGT1 polypeptide A1
(UGT1A1) gene region.
Conclusion: The UGT1A1 enzyme catalyses the detoxification of several drugs and the turnover of many xenobiotic and
endogenous compounds by glucuronidating its substrates. These data indicate that UGT1A1-associated processes are also
involved in the regulation of serum cf-DNA concentrations.
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Introduction
Circulating cell-free DNA (cf-DNA) was first described in 1940s
[1], and it has frequently been used as a convenient indicator of
cell death and tissue damage in various acute and chronic
disorders [2–4]. Detectable amounts of cf-DNA are present in
healthy individuals, yet significantly increased plasma/serum levels
of cf-DNA have been reported in patients with acute cardiovas-
cular disease, sepsis, cancer and pre-eclampsia [2–4]. Circulating
nucleosomal DNA has also been proposed as a major autoantigen
in systemic lupus erythematosus [5] and as a potential player in
lupus nephritis [6]. Additionally, genomic DNA fragments
released during sterile thyroid injury may also trigger autoreactiv-
ity-related thyroid dysfunction [7]. Other potentially detrimental
functions implicated for cf-DNA include the horizontal transfer of
oncogenic sequences (i.e. genometastasis) [8] and the creation of
a proinflammatory milieu in the circulation [9]. Endogenous or
microbial DNA are also known to act as alerting signals to the host
immune system, and various soluble, membrane-bound and
intracellular receptors that can recognise DNA have been
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identified. These receptors include pattern recognition molecules
such as collectins, ficolins, pentraxins, soluble CD14 and C1q [10];
Toll-like receptors (TLRs) [11]; the high-mobility group box
(HMGB) proteins [12]; components of the inflammasome [13];
and extrachromosomal histone H2B [7]. Upon sensing DNA,
these receptors can mount an immuno-inflammatory response to
eliminate the circulating DNA and prevent anti-DNA autoimmu-
nity.
Despite its proven utility in diagnosis and in determining various
clinical conditions, many aspects ofthe origin, metabolism and
non-pathological fluctuations of cf-DNA remain unresolved.
According to the current understanding, the majority of cf-DNA
is derived from apoptotic or necrotic cells; however, active
secretion by leukocytes may also contribute to the pool of
circulatory DNA [4]. Serum cf-DNA is hypothesised to consist
of both free DNA and particle-bound forms [4], yet the
relationships between cf-DNA composition, originating cell types
and the given clinical conditions are unclear.
Studies in mice have demonstrated that injected DNA,
including single-stranded DNA (ssDNA), double-stranded DNA
(dsDNA), nucleosomal core particles and oligonucleotides, is
cleared from the system very rapidly, in less than 40 minutes,
and that the major organ responsible for the solubilisation and
generation of DNA degradation products is the liver [14–16].
Nevertheless, the clearance kinetics of these distinct DNA
speciesare somewhat different, and the induction of the acute
phase response or co-injection of the acute phase reactants serum
amyloid P (SAP) and C-reactive protein (CRP) causes a delay in
chromatin clearance, concomitant with an increased localisation of
cf-DNA to the liver [17]. However, it has also been demonstrated
that macrophages play an essential role in processing the cf-DNA
released from dead or dying cells [18,19]. Data regarding the
corresponding cf-DNA dynamics in humans are very scarce, but it
has been reported that foetal cf-DNA has a mean half-life of
16.3 minutes in the maternal plasma and that plasma nucleases
have only a partial role in the removal of foetal DNA [20].
To identify the genetic determinants of serum cf-DNA levels
and thus elucidate the mechanisms involved in cf-DNA turnover,
we performed a genome-wide association analysis (GWA) in
a cohort of young adults participating in the Cardiovascular Risk
of Young Finns study.
Results
The characteristics of the study population are presented in
Table 1. In addition to age and insulin concentration, all of the
variables tested differed significantly between women and men
(Table 1). In the GWA, a total of 110 single nucleotide
polymorphisms (SNPs) were associated with serum cf-DNA levels
with a genome wide significance level of p,561028. All 110 SNPs
localised to the UDP-glucuronosyltransferase 1 (UGT1) family locus on
chromosome 2q37, and the most significant SNPs resided in the
UGT1 polypeptide A1 (UGT1A1) gene region (Figure 1 and Figure 2).
In the UGT1 gene family region, we observed a major haploblock
that could be further divided into nine sub-blocks (using the four
gamete rule in HaploView). The four top SNPs on UGT1A1
belong to the sub-block no. 8, which spans approximately 11 kb,
and these SNPs appeared to be in virtually perfect linkage
(r2 = 0.999121.0). None of the significant SNPs in the sub-block
no. 8 resided in exonic regions. However, among the significant
SNPs outside this haploblock, three non-synonymous SNPs
(rs6759892, rs2070959, rs1105879, p = 8.261021823.4610214)
were identified in the coding region of UGT1A6 (Figure 2). In
addition, three significant SNPs (rs17864701, rs4663967,
rs6741669, p = 1.261022121.1610217) were detected in the
Table 1. Characteristics of the study population.
Variable Women (n=1018) Men (n =823) p for difference
Mean S.D. Mean S.D.
Age (years) 31.7 5.0 31.7 5.0 N.S.
BMI (kg/m2) 24.4 4.5 25.7 4.2 ,0.001
Waist circumference (cm) 79.2 11.2 90.0 11.0 ,0.001
Systolic blood pressure (mmHg) 113 12 121 13 ,0.001
Diastolic blood pressure (mmHg) 69 10 73 11 ,0.001
Total cholesterol (mmol/L) 5.02 0.87 5.20 1.00 ,0.001
HDL-cholesterol (mmol/L) 1.39 0.29 1.16 0.28 ,0.001
LDL-cholesterol (mmol/L) 3.11 0.76 3.40 0.89 ,0.001
Triglycerides (mmol/L)* 1.0 0.8–1.3 1.2 0.9–1.8 ,0.001
Insulin (mU/L)* 6 5–9 6 4–9 N.S.
Glucose (mmol/L)* 4.9 4.6–5.1 5.1 4.9–5.4 ,0.001
Homocysteine (mmol/L)* 8.5 7.2–10.1 10.1 8.7–11.7 ,0.001
cf-DNA (mg/ml) 0.755 0.135 0.862 0.111 ,0.001
CRP (mg/L)* 0.84 0.35–2.30 0.59 0.30–1.42 ,0.001
Alcohol (drinks per week)* 2 0–5 6 1–13 ,0.001
Smoking daily (% of total){ 19.3 29.4 ,0.001
Use of COCs (% of total) 24.9
*Median values and interquartile range (IQR), Mann-Whitney test for between-group differences.
{Chi-squared test for differences between groups.
Abbreviations: BMI,body mass index; cf-DNA, cell-free DNA; COCs, combined oral contraceptives; CRP, C-reactive protein; N.S., not significant.
doi:10.1371/journal.pone.0035426.t001
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promoter region of DNAJB3 (Figure 2). The top SNPs in each of
the nine sub-blocks are presented in Table 2.
When the selected tag SNPs from each sub-block were analysed
using the stepwise AIC model selection algorithm, only the tag
SNP rs4148324 which identifies the sub-haploblock no. 8
containing the four top SNPs, remained in the model. This SNP
was found to explain 5.3% of the total variation in serum cf-DNA
levels. In addition, conditioning the analysis on the top SNP
rs4148324 (i.e. additional adjustment of the model with the top
SNP) did not reveal any other SNPs associated with cf-DNA levels
at a genome-wide significance level (all p-values.0.4).
An interaction network for UGT1A1 constructed with IPA
(Ingenuity Pathway Analysis) revealed that several molecules in the
UGT1A1 interaction network are connected to DNA metabolism,
quantity, fragmentation and synthesis of DNA (Figure 3). In
addition, molecular connections to HMGB signalling and TLR
signalling were observed for UGT1A1 in the IPA Canonical
Pathway analysis (Figure 3)
Discussion
The circulating cf-DNA concentration has been shown to
increase during pathological processes, reflecting the rate of
cellular death and tissue damage. However, the regulation and
metabolism of cf-DNA have received much less attention, and
data regarding the turnover of cf-DNA are scarce. In this study, we
demonstrate that a novel candidate gene, UGT1A1, may
contribute to the regulation of serum cf-DNA in young adults.
The UGTs comprise a family of enzymes that primarily transfer
glucuronic acid to hydroxyl, carboxylic acid and amine group-
bearing compounds to facilitate the catabolism and clearance of
these compounds [21]. Because a wide variety of compounds
contain these groups, glucuronidation provides a common mech-
anism for the elimination of several endobiotics, xenobiotics and
drugs. The UGT1A locus encodes several isoforms of the enzyme,
each with a tissue-specific expression pattern [21]. Although the
liver is the major producer of UGT1A1, the expression of this
isoform has also been detected in the bile duct, the stomach, the
small intestine, the kidneys, the bladder, the uterus and the colon
[21,22]. Interestingly, the expression of UGT1A1 has recently
been demonstrated in human peripheral blood mononuclear cells
[23].
Due to the strong linkage disequilibrium between the SNPs in
the UGT1 region (Figure 2) we cannot completely rule out the
involvement of the other significant SNPs, such as those in the
coding region of UGT1A6 or in the promoter of DNAJB3, in the
regulation of cf-DNA levels. Nevertheless, the main signal can be
confined to the sub-block of the four top UGT1A1 SNPs because
the significance of the p-values of the other SNPs decreases along
with the increase in distance from this sub-block (Table 2 and
Figure 2).
One of the best characterised functions of UGT1A1 is the
glucuronidation of bilirubin [21], and numerous recent GWA
studies have identified UGT1A1 alleles as the major regulators of
serum bilirubin levels [24]. The four most significant SNPs
associated with serum cf-DNA levels in this study (rs4148324,
rs6742078, rs4148325 and rs887829) have also been identified as
regulators of serum bilirubin concentrations [24]. The effect of
these SNPs on bilirubin levels is, however, reported to be due to
a functional TA-repeat polymorphism in the UGT1A1 promoter
TATA-box area; recent conditional linkage scans of this TA-
repeat association demonstrated that it accounts for the linkage
peaks observed for the other associated loci in the gene region
[25,26]. Given that the ancestral alleles of the rs4148324,
rs6742078, rs4148325 and rs887829 SNPs are in strong linkage
with the wild-type form of the TA-repeat polymorphism (TA6,
rs8175347), and because all of these variants belong to the same
haploblock in our population, we assume that the same regulation
pattern holds true for both serum cf-DNA and bilirubin levels. The
TA6 form of the repeat polymorphism is associated with lower
bilirubin levels due to higher promoter activity (via optimal
transcription factor IID binding), resulting in higher UGT1A1
enzyme levels and enhanced bilirubin glucuronidation and
Figure 1. Manhattan plot of the genome-wide analysis of SNPs associated with serum cf-DNA levels. SNPs with significant genome-wide
p-values (p,561028) are indicated in green.
doi:10.1371/journal.pone.0035426.g001
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clearance [27]. Because we observed lower cf-DNA levels in
subjects bearing the wild type alleles (ß =20.3358) of the four top
SNPs in comparison with the minor allele carriers, we suggest that
higher UGT1A1 production, or some cellular process associated
with UGT1A1 induction, contributes to more effective turnover of
serum cf-DNA.
Animal studies have demonstrated that the liver is the major site
of cf-DNA clearance, although some portion of the circulating
DNA also localises to other organs, such as the kidneys and spleen
[14,16,17]. However, in humans, foetal cf-DNA has been shown
to be cleared rapidly from the maternal circulation, and plasma
nucleases have only a partial effect on cf-DNA disposal [20].
Moreover, relatively large DNA fragments (.150 base pairs)
originating from non-renal or urinary tract tissues have been
detected in the urine [28], indicating that the complete digestion of
cf-DNA by nucleases is not required for its excretion. Beyond these
observations, the metabolism and fates of different cf-DNA forms
are unknown. Although our data does not provide a mechanistic
basis of UGT1A1-mediated cf-DNA clearance, we propose that
the metabolism of cf-DNA may be facilitated by UGT1A1, either
directly by glucuronidation or indirectly via the interactions
between UGT1A1 and the molecules related to DNA sensing and
processing (Figure 3). It is also possible that a portion of the cf-
DNA is endocytosed and/or co-processed with the traditional
UGT1A1 substrates, such as the bilirubin-albumin complex [29].
Nevertheless, physiological interactions between UGT1A1 and
nucleotides have been demonstrated [30] and the glucuronidation
of a 29,39-dideoxynucleoside compound, the 39-Azido-39-deox-
Figure 2. UGT1 regional association plot and haploblock structure of the genome-wide analysis of SNPs associated with serum cf-
DNA levels. The violet circles indicate the top SNPs in the UGT1A1 region, the circled triangles indicate the non-synonymous SNPs in UGT1A6 region,
and the circled squares and circles indicate the SNPs in the DNAJ3B promoter region. The colour of the spots indicates LD (data from HapMap II CEU)
with the index SNPs (violet spots). The blue line shows the recombination rate across the region (data from HapMap II CEU). The nine sub-blocks in
the major haploblock are separated with black lines. The sub-block containing the four top SNPs is separated with a thick black line.
doi:10.1371/journal.pone.0035426.g002
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ythymidine (AZT), has been demonstrated, although this reaction
is performed by the UGT2B7 enzyme [31]. However, at the
present time, we can only speculate whether these observations are
related to the glucuronidation of endogenous cf-DNA during the
course of its cellular internalisation or (apoptotic) release. Neither
can we exclude the possibility that the actual UGT1A1 substrate
might be some lipophilic or proteinaceous structure associated
with cf-DNA. Furthermore, the potential involvement of extrahe-
Table 2. The top SNPs in each of the 9 sub-blocks in the UGT1A gene region (see Figure 2).
SNP{ Sub-blockLocus (bp)
Ancestral
allele Minor allele MAF b (S.E.) p* Imputed Location
rs17864683 1 234243948 A C 0.3221 0.3246 (0.0352) 2.06E214 yes intron, UGT1A10
rs10168416 2 234261826 G C 0.4230 0.3236 (0.0325) 2.98E215 no intron, UGT1A8
rs1105879 3 234266941 C A 0.4603 0.3127 (0.0324) 8.20E218 no missense, UGT1A6
rs17863787 4 234275833 G T 0.3592 0.3092 (0.0338) 1.40E-19 no intron, UGT1A6
rs6744284 5 234290036 T C 0.3710 0.2818 (0.0335) 3.04E220 no intron, UGT1A6
rs6722076 6 234312056 A G 0.3705 0.2824 (0.0334) 1.25E221 yes intron, UGT1A6
rs17864701 7 234317456 T C 0.3722 0.2591 (0.0335) 1.19E221 yes intron, UGT1A6
rs887829 8 234333309 A G 0.3983 0.3358 (0.0331) 1.59E223 no intron, UGT1A1
rs6742078 234337378 T G 0.3983 0.3358 (0.0331) 1.59E223 no intron, UGT1A1
rs4148324 234337461 G T 0.3983 0.3358 (0.0331) 1.59E223 no intron, UGT1A1
rs4148325 234338048 T C 0.3983 0.3358 (0.0331) 1.59E223 no intron, UGT1A1
rs11690786 9 234357356 T C 0.3839 0.2711 (0.0337) 9.67E217 yes intron, HEATR7B1
The four SNPs that are associated most significantly with serum cf-DNA levels are in sub-block 8.
{For each SNP, the ancestral allele was modelled, and the b coefficient represents the change in cf-DNA level (mg/ml) with one additional copy of the ancestral allele.
*Adjusted for age, sex, BMI and genetic East-West stratification in the Finnish population.
Abbreviations: SNP, single nucleotide polymorphism; Chr, chromosome; bp, base pairs; MAF, minor allele frequency; S.E., standard error.
doi:10.1371/journal.pone.0035426.t002
Figure 3. The UGT1A1 interaction network generated using the Ingenuity Pathway Analysis. The molecular relationships connecting
UGT1A1 to DNA metabolism synthesis, fragmentation and quantity of DNA are indicated with Fx symbols, and the associated Canonical Pathways are
indicated with CP symbols. Abbreviations: AHR, aryl hydrocarbon receptor; HMGB1, high-mobility group box protein 1; IL1B, interleukin-1 beta; MYC,
v-myc myelocytomatosis viral oncogene homolog; NR1I3, nuclear receptor subfamily 1, group I, member 3; PPARGC1A, peroxisome proliferator –
activated receptor gamma coactivator 1 alpha; RELA, v-rel reticuloendotheliosis viral oncogene homolog A (avian); TLR4, Toll-like receptor 4.
doi:10.1371/journal.pone.0035426.g003
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patic UGT1A1-expression sites, such as leukocytes [23] or
intestinal cells [32], in cf-DNA turnover cannot be addressed by
our data.
Our statistical model for genetic variation in the UGTA1
explains only 5.3 % of the total variation in cf-DNA levels,
although the association is highly statistically significant
(p = 1.6610223). The somewhat modest coefficient of determina-
tion can be explained by the complex nature of the serum cf-DNA;
different forms of cf-DNA might be assigned to different clearance
pathways with dissimilar kinetics and saturability. It is also known
that the serum contains higher cf-DNA levels than the plasma,
allegedly due to the release of genomic DNA from leukocytes
during blood clotting [33] Recently, however, this view has been
challenged by the observation that leukocyte rupture is not the
major factor causing increased serum cf-DNA levels [34].
Nevertheless, the strong association suggests a significant biological
role for UGT1A1 in regulating cf-DNA levels, especially because
no other polymorphisms outside the reported UGT1A1 loci
emerged with genome-wide significance when the analysis was
adjusted using the top SNP (rs4148324).
In conclusion, the results of this GWA study demonstrate that
UGT1A1 polymorphisms are associated with serum cf-DNA levels
in young Finns. We propose that UGT1A1-associated processes
are, either directly or indirectly, involved in the regulation of cf-
DNA concentration. These results, however, are limited to one
study cohort which is a major limitation of our study. Therefore
the results should be replicated in an independent study cohort,
and further investigation to establish the exact role of UGT1A1 in
cf-DNA turnover is warranted.
Materials and Methods
Study population
The study population consisted of 1841participants in the
Cardiovascular Risk in Young Finns study (aged 24–39 years;
1018 women and 823 men). The study was approved by the local
ethics committees (the University Hospitals of Helsinki, Turku,
Tampere, Kuopio and Oulu) and was conducted following the
guidelines of the Declaration of Helsinki. All participants gave
their written informed consent. For a detailed cohort description
and the assessment of the variables listed in Table 1, see [35] and
the references therein. The data in this study were from individuals
with successful cf-DNA measurements and genotyping and who
participated in the follow-up study in 2001.
Quantification of serum cf-DNA
Total circulating cf-DNA was determined directly in previously
unthawed serum using the fluorescence-based Quant-iTTM high-
sensitivity DNA assay kit and a QubitH fluorometer (Invitrogen,
Carlsbad, CA, USA). All samples were analysed in duplicate, and
the mean of the two measurements was used as the final value. At
the mean serum cf-DNA levels of 0.650 mg/ml, the assessed intra-
and inter-day variation coefficients were 2.2% and 4.7%,
respectively. At the mean serum cf-DNA level of 1.02 mg/ml,
the intra- and inter-day variation coefficients were 3.0% and
5.8%, respectively.
Genotyping
Genotyping was performed at the Welcome Trust Sanger
Institute using a custom made Illumina Human 670 k BeadChips.
Genotypes were determined using the Illumina clustering
algorithm [36]. Fifty-sixsamples failed the Sanger genotyping
pipeline QC criteria (i.e., duplicated samples, heterozygosity, low
call rate, or Sequenom fingerprint discrepancies). Three samples
were removed due to a low genotyping call rate (,0.95) and 54
samples were excluded for possible relatedness (pi.hat.0.2). A
total of 11,766 single SNPs were excluded due to deviation from
Hardy-Weinberg equilibrium (HWE) test (p#1e-06), 7,746 SNPs
failed the missingness test (call rate,0.95) and 34,596 SNPs failed
the frequency test (MAF,0.01). After quality control, 546,677
genotyped SNPs remained available for further analysis. Genotype
imputation was performed using MACH 1.0 [37,38] and HapMap
II CEU (release 22) samples as reference. After imputation,
2,543,887 imputed SNPs were available. SNPs with squared
correlations $0.3 between imputed and true genotypes were
considered well imputed.
Statistical methods
The comparison of the basic study population variables
presented in Table 1 was conducted with the Student’s t-test,
Mann-Whitney’s test or chi-squared test. Prior to the GWA, all
continuous variables were subjected to inverse normal trans-
formation to minimise the incidence of type I errors and to reduce
the impact of outliers [39]. A stepwise backward model (Akaike
information criterion, AIC) was used to determine which
covariates explained the most of the variation in the cf-DNA
levels. In addition to the variables listed in Table 1, genetic main
identity-by-descent (IBD) clustering components and interactions
between age and gender as well as smoking status and the use of
alcohol were included in the model. The variables that remained
in the model and were thus used as the adjustment covariates in
GWA were gender, age, systolic blood pressure, fasting glucose,
triglycerides, CRP, homocysteine, daily smoking, use of alcohol,
use of combined oral contraceptives, main IBD components and
the gender*age and daily smoking*use of alcohol the interaction
terms. These factors were observed to account for 30.5% of the
variation in cf-DNA levels. To reveal other SNPs potentially
associated with serum cf-DNA, the analysis was additionally
adjusted with the top SNP, rs4148324. Standardised residuals
were extracted from the model, and association analysis was
performed using linear regression with an assumption of an
additive genetic effect. PLINK [40] was used for the true
genotyped SNPs, and ProbABEL [41] was used for imputed
genotype dosages. If the same SNP was available in both
genotyped and imputed form, the genotyped form was displayed
and included in the results. A commonly accepted threshold for
genome-wide statistical significance level (p,561028) was used to
identify significant SNPs. Manhattan and Q-Q plots were drawn
to confirm the validity of the analysis. The genomic inflation factor
(lambda) was 0.9996475. The variance in serum cf-DNA level
explained by each SNP (R2) was calculated as follows: R2= 1/
[1+(number of samples22)6(SE of SNP/beta estimate of SNP)2].
The individual genotype data for genome-wide significant SNPs in
the same region were extracted from both the genotyped and
imputed data; then the allele dosages of the imputed SNPs were
rounded to best guess genotypes and transferred to Haploview
[42] for haploblock analysis and tag SNP identification. Haplo-
blocks were defined using the four gamete rule in Haploview, and
the SNP with the lowest p-value in each haploblock was selected as
the tag SNP. All tag SNPs were analysed with stepwise backward
AIC to identify the potential independent signals in different
haploblocks. Unless otherwise noted, the statistical analyses were
performed the appropriate packages in R (MASS for stepwi-
se AIC).
To identify the potential interactions via which UGT1A1 could
be connected to cf-DNA regulation, a graph of the UGT1A1
molecular network and associated functions and Canonical
Pathways was generated using IPA (IngenuityH Systems, www.
UGT1A1-Mediated Regulation of Serum cf-DNA
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ingenuity.com). In the IPA network analysis, the biological
relationship between two molecules is represented as an edge
(continuous or dashed line). All edges are supported by at least one
reference from the literature, textbook or canonical information
stored in the Ingenuity Knowledge Base.
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